CATALYST PHARMACEUTICALS, INC.CPRX

Market cap

$2.8B

P/E ratio

	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Product Revenue Net	-	-	-	-	-	-	-	-	-	-	138	214	397	489
License and other revenue	-	-	-	-	-	-	-	-	-	-	3	0	2	2
Total revenues	-	-	-	-	-	-	-	-	102	119	141	214	398	492
Cost of sales	-	-	-	-	-	-	-	-	15	17	22	34	52	69
Research and development	26	28	36	10	12	11	11	20	19	16	17	20	93	13
Selling, general and administrative	-	-	-	-	-	-	-	-	37	44	50	58	134	178
Amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	33	37
Total operating costs and expenses	-	-	-	-	-	-	-	-	-	-	-	112	311	297
Operating income	-6,082,139	-5,221,140	-10,311,658	-14,591,428	-20,398,352	-19,280,201	-18,679,636	-35,295,165	32	41	52	102	87	195
Other income, net	-	-	-	76,233	100,389	321,612	454,163	1	2	586,897	0	3	8	21
Net income before income taxes	-	-	-	-	-20,232,958	-18,072,452	-18,412,377	-34,003,514	33	42	53	105	95	216
Income tax provision	-	-	-	-	-	-	-	-	2	-33,092,926	13	22	23	52
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71	164
Basic	-	-	-	-	-	-	-	-	0.31	0.72	0.38	0.8	0.67	1.38
Diluted	-	-	-	-	-	-	-	-	0.3	0.71	0.37	0.75	0.63	1.31
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71	164
Unrealized gain (loss) on available-for-sale securities, net of tax of ($20), $4 and ($54), respectively	-	-	-	-	-	-	-	-20,248	29,753	21,827	-0	0	-0	0
Comprehensive income	-	-	-	-	-	-	-	-34,023,762	32	75	39	83	71	164